US panel to review Genzyme's Myozyme for late-onset Pompe disease
This article was originally published in Scrip
Executive Summary
The US FDA's endocrinologic and metabolic drugs advisory panel will meet on October 21st to discuss Genzyme's BLA for Myozyme (alglucosidase alfa) for the treatment of late onset Pompe disease. The agency approved Myozyme in 2006 based on efficacy data in patients with infantile-onset disease, and Genzyme conducted a study in late-onset patients as a postmarketing commitment. The BLA was filed in May and is undergoing a priority review, with a November 29th user fee date. It seeks FDA approval to manufacture the enzyme-replacement therapy in a 2,000 litre bioreactor. The agency previously approved production at a 160 litre bioreactor, but the agency has determined that Myozyme produced at the two scales should be classified as different products because of differences in the carbohydrate structures. Agency approval of the BLA would result in the availability of two commercial versions of Myozyme in the US produced at different scales.
You may also be interested in...
Drug Shortages, Inspections In Focus At US FDA Appropriations Hearing
Commissioner Robert Califf discussed the agency’s request for $12.3m to address shortages and legislation to require that manufacturers provide more detailed information about increased demand and supply chain vulnerabilities.
Clinical Trial Diversity Requires Sponsors Work With An Assortment Of Patient Advocates, Community Organizations
US FDA oncology officials are concerned that the entities sponsors are consulting in developing and implementing clinical trial diversity plans are not sufficiently diverse themselves and do not represent patients in underserved communities.
US FDA Drugs Center Launches Clinical Trial Innovation Hub With Demonstration Projects
CDER’s Center for Clinical Trial Innovation (C3TI) will support innovative clinical trial approaches designed to improve the quality and efficiency of drug development and regulatory decision-making. The initiative includes demonstration projects on Bayesian analyses, selective safety data collection and point-of-care trials.